Owner Scorecard


← All companies ← TER Manual TEX → ← TBPH Pharmaceuticals TGTX →

TEVA, Teva Pharmaceutical Industries Limited

Pharmaceuticals consumer brand Distress / turnaroundRevenue in runoff

We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world.

From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients' needs, now and in the future.

Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets.

Latest annual: FY2025 10-K
TEVA · Teva Pharmaceutical Industries Limited
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$17.3B
+4.3% YoY · 1% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $17.3B 5-yr avg $16.1B
Gross margin 52% 5-yr avg 49%
Operating margin 9.3% 5-yr avg 1.9%
ROIC 8% 5-yr avg 2%
Owner-earnings margin 8% 5-yr avg 5%
Free cash flow margin 8% 5-yr avg 5%

Next report Est. 10/26–11/6 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~36 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is led by United States (53%) and Europe (29%), with 2 more segments behind.
Situation
Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Revenue in runoff. Revenue has shrunk about 3% a year across the record while operations still generate cash.
What moves the needle
Operating margin has reached 12% at its best but run negative through the cycle (median −2.2%) on a 48% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Inventory runs near 24% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −2%, above 15% in 0 of 8 years). By owner earnings: roughly 6% of revenue reaches owners as cash, consistently. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Revenue spreads across 4 segments, the largest United States at 53%.

Revenue by reportable segment, FY2025
  • United States53%$9.2B
  • Europe29%$5.0B
  • International Markets13%$2.2B
  • Other Activities5%$870M

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$21.9B$21.9B$18.3B$16.9B$16.7B$15.9B$14.9B$15.8B$16.5B$17.3B$17.3BRevenueRevenue
$11.7B$10.6B$8.3B$7.5B$7.7B$7.6B$7.0B$7.6B$8.1B$8.9B$9.1BGross profitGross prof.
53%49%45%45%46%48%47%48%49%52%52%Gross marginGross mgn
23%22%23%23%22%22%23%22%22%23%24%SG&A / revenueSG&A/rev
2%1%1%6%6%6%1%6%6%6%10%R&D / revenueR&D/rev
$2.2B($17.5B)($1.6B)($443M)($3.6B)$1.7B($2.2B)$433M($303M)$2.2B$1.6BOperating incomeOp. inc.
9.8%−80.0%−9.0%−2.6%−21.4%10.8%−14.7%2.7%−1.8%12.5%9.3%Operating marginOp. mgn
$824M($18.4B)($2.6B)($1.3B)($4.4B)$658M($3.2B)($624M)($1.3B)$1.2BPretax incomePretax
$329M($16.3B)($2.1B)($999M)($4.0B)$417M($2.4B)($559M)($1.6B)$1.4B$706MNet incomeNet inc.
Cash flow & returns
$3.9B$2.2B$2.4B$748M$1.2B$798M$1.6B$1.4B$1.2B$1.6B$1.9BOperating cash flowOp. cash
$1.5B$2.1B$1.8B$1.7B$1.6B$1.3B$1.3B$1.2B$1.1B$1.0B$988MDepreciation & amortizationD&A
$1.9B$16.2B$2.6B($94M)$3.5B($1.1B)$2.6B$653M$1.7B($920M)$36MWorking capital & otherWC & other
$901M$874M$651M$525M$578M$562M$548M$526M$498M$501M$551MCapexCapex
4.1%4.0%3.6%3.1%3.5%3.5%3.7%3.3%3.0%2.9%3.2%Capex / revenueCapex/rev
$3.0B$1.4B$1.8B$223M$638M$236M$1.0B$842M$749M$1.1B$1.3BOwner earningsOwner earn.
13.6%6.2%9.8%1.3%3.8%1.5%7.0%5.3%4.5%6.7%7.8%Owner earnings marginOE mgn
$3.0B$1.4B$1.8B$223M$638M$236M$1.0B$842M$749M$1.1B$1.3BFree cash flowFCF
13.6%6.2%9.8%1.3%3.8%1.5%7.0%5.3%4.5%6.7%7.8%Free cash flow marginFCF mgn
$36.1B$0$0$0$7M$0$15M$0$0AcquisitionsAcquis.
$1.3B$901M$12M$12MDividends paidDiv. paid
($34.4B)$3.4B$1.9B$1.4B$863M$1.5B$656M$968M$792M$737MInvesting cash flowInv. cash
$25.2B($5.8B)($3.4B)($1.9B)($1.9B)($2.2B)($1.5B)($1.9B)($1.8B)($2.2B)Financing cash flowFin. cash
($660M)$54M($142M)$16M$8M($128M)($123M)($30M)($174M)$21MExchange-rate effectFX
($6.0B)($25M)$819M$193M$202M$21M$636M$393M$74M$256MChange in cashΔ cash
-29%-3%-1%-8%4%-7%-1%10%8%ROICROIC
1%-94%-15%-7%-40%4%-31%-7%-31%18%9%Return on equityROE
−3%−99%−15%9%Retained to equityRetained/eq
Balance sheet
$988M$963M$1.8B$2.0B$2.2B$2.2B$2.8B$3.2B$3.3B$3.6B$3.7BCash & investmentsCash+inv
$7.5B$7.1B$5.8B$5.7B$4.6B$4.5B$3.7B$3.4B$3.1B$3.7B$3.5BReceivablesReceiv.
$5.0B$4.9B$4.7B$4.4B$4.4B$3.8B$3.8B$4.0B$3.0B$3.2B$3.2BInventoryInvent.
$2.2B$2.1B$1.9B$1.7B$1.8B$1.7B$1.9B$108M$158M$225M$2.7BAccounts payablePayables
$10.3B$10.0B$8.7B$8.4B$7.2B$6.7B$5.6B$7.3B$5.9B$6.7B$4.0BOperating working capitalOper. WC
$17.2B$15.4B$13.8B$13.5B$13.0B$12.6B$12.1B$12.5B$12.6B$13.9B$13.8BCurrent assetsCur. assets
$18.5B$17.9B$14.3B$13.7B$13.2B$11.0B$11.5B$12.2B$12.8B$13.5B$15.6BCurrent liabilitiesCur. liab.
0.9×0.9×1.0×1.0×1.0×1.1×1.1×1.0×1.0×1.0×0.9×Current ratioCurr. ratio
$8.1B$7.7B$6.9B$6.4B$6.3B$6.0B$5.7B$5.8B$4.6B$4.1BNet PP&ENet PP&E
$44.4B$28.4B$24.9B$24.8B$20.6B$17.6B$17.2B$17.2B$15.1B$16.0B$15.8BGoodwillGoodwill
$93.1B$70.6B$60.7B$57.5B$50.6B$47.7B$44.0B$43.5B$39.3B$40.7B$39.9BTotal assetsAssets
$33.3B$31.7B$28.5B$26.5B$25.5B$23.1B$21.3B$19.9B$17.8B$16.9B$16.6BTotal debtDebt
$32.3B$30.7B$26.7B$24.5B$23.3B$21.0B$18.5B$16.7B$14.5B$13.3B$13.0BNet debt / (cash)Net debt
3.9×-20.0×-1.8×-0.5×-4.0×1.9×-2.4×0.4×-0.3×2.4×1.8×Interest coverageInt. cov.
$58.1B$51.9B$44.9B$42.4B$39.6B$36.4B$35.4B$35.4B$33.6B$32.8BTotal liabilitiesTotal liab.
$1.7B$1.4B$1.1B$1.1B$1.0B$966M$794M$620M$7M$4MNoncontrolling interestsNCI
$33.3B$17.4B$14.7B$14.0B$10.0B$10.3B$7.8B$7.5B$5.4B$7.9B$7.8BShareholders’ equityEquity
0.6%0.6%0.8%0.7%0.8%0.7%0.8%0.8%0.7%0.9%1.0%Stock comp / revenueSBC/rev
$900M$17.1B$3.0B$4.6B$2.0B$700M$1.3BGoodwill written downGW imp.
Per share
961M1.02B1.02B1.09B1.09B1.11B1.11B1.12B1.13B1.16B1.16BShares out (diluted)Shares
$22.79$21.51$17.90$15.48$15.21$14.34$13.45$14.16$14.63$14.84$14.93Revenue / shareRev/sh
$0.34$-16.01$-2.11$-0.92$-3.64$0.38$-2.20$-0.50$-1.45$1.21$0.61EPS (diluted)EPS
$3.11$1.33$1.76$0.20$0.58$0.21$0.94$0.75$0.66$0.99$1.16Owner earnings / shareOE/sh
$3.11$1.33$1.76$0.20$0.58$0.21$0.94$0.75$0.66$0.99$1.16Free cash flow / shareFCF/sh
$1.36$0.89$0.01$0.01Dividends / shareDiv/sh
$0.94$0.86$0.64$0.48$0.53$0.51$0.49$0.47$0.44$0.43$0.47Cap. spending / shareCapex/sh
$34.69$17.09$14.40$12.81$9.16$9.28$7.03$6.71$4.75$6.80$6.68Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share−4.7%/yr−0.5%/yr
Owner earnings / share−12.0%/yr+11.1%/yr
EPS+15.1%/yr
Dividends / share−90.7%/yr (2-yr)−90.7%/yr (2-yr)
Capital spending / share−8.3%/yr−4.0%/yr
Book value / share−16.6%/yr−5.8%/yr

The year, in the company's words

the filing →

Verbatim from the 10-K's management discussion. Each sentence is shown only because its subject, direction, and stated figures check out against the filed numbers on this page. The words are the company's; the arithmetic is the record's.

  • United States+14.3%
    “United States Revenues Revenues from our United States segment in 2025 were $9,186 million, an increase of $1,152 million, or 14%, compared to 2024, mainly due to higher revenues from our key innovative products AUSTEDO, AJOVY, and UZEDY, development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A), as well as higher revenues from generic products (including biosimilars).”
    ✓ figure matches the filed record

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cash

Each year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.

FY2016FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported $1.4B of profit but $1.1B of owner earnings: $262M less than the profit line, taken out by capital spending and the timing of cash.

Reported net income$1.4B
Owner earnings$1.1B · 7% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$1.4B($1.6B)($559M)($2.4B)$417M
Depreciation & amortizationnon-cash charge added back+$1.0B+$1.1B+$1.2B+$1.3B+$1.3B
Stock-based compensationreal costnon-cash, but a real cost+$157M+$123M+$121M+$124M+$119M
Working capital & othertiming of cash in and out, other non-cash items−$920M+$1.7B+$653M+$2.6B−$1.1B
Cash from operations$1.6B$1.2B$1.4B$1.6B$798M
Capital expenditurecash put back in to keep running and to grow−$501M−$498M−$526M−$548M−$562M
Owner earnings$1.1B$749M$842M$1.0B$236M
Owner-earnings marginowner earnings ÷ revenue7%5%5%7%1%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $157M), owner earnings is nearer $991M.

Much of fiscal 2025's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Adequate
    Operating income $2.2B ÷ interest expense $916M
    What this means

    Comfortable in a normal year, but below the margin of safety Graham looked for. Worth checking how stable the coverage has been across a full cycle.

  • How heavy is the debt, net of cash? $27.1B · 12.6× operating profit
    Heavy net debt
    Cash $3.6B − debt $30.6B
    What this means

    Netting $3.6B of cash and short-term investments against $30.6B of debt leaves $27.1B owed, about 12.6× a year's operating profit (14.2× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 78 + DIO 139 − DPO 10 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Below average through the cycle
    8-yr median, range -29%–10%; 6% latest = NOPAT $2.2B ÷ invested capital $35.0B
    Industry peers: median 13%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 8 years (it ran 6% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Solid through the cycle
    10-yr median margin, range 1%–14%; latest $1.1B = operating cash $1.6B − maintenance capex $501M
    Industry peers: median 22%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 7% of revenue this year, a 6% median across 10 years. Treating stock comp as the real expense it is (less $157M of SBC) leaves $991M.

  • Cash-backed
    Cash from ops $1.6B ÷ net income $1.4B
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.50×
    Harvesting
    Capex $501M ÷ depreciation & amortization as filed $1.0B
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Modest selling cost
    Selling and marketing $2.7B ÷ revenue $17.3B
    What this means

    Sales and marketing as a share of revenue, kept apart from administrative overhead because it answers a different question: how much a business must spend to win the next customer. A company whose product pulls customers in spends little here and keeps the difference; one that must buy its growth is running to stand still, and the spending has to keep rising for revenue to keep rising. Read it beside the growth rate, not alone.

  • Is the buyback buying ownership, or mopping up? 0.9%
    The count is rising
    Stock compensation $157M (fiscal 2025), 0.9% of revenue · no repurchases · diluted shares +4.8% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 1 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Pass
    Revenue ≥ $2B · $17.3B
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Miss
    Current ratio ≥ 2× · 1.04×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Miss
    Debt ≤ working capital · $30.6B vs $490M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 7 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · 3 of 10 yrs
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.23/share (latest year $1.21), the averaged base the calculator's gate runs on, and book value is $6.79/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 3 of 10
    What this means

    Lost money in 7 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −26% → 4% (3-yr avg ends)

    In the filing’s words The filing ties gains to its own pricing, but names price competition too — pricing power that is real yet contested, not unopposed. The margin shows who is winning.

    What this means

    Through the cycle the operating margin widened — about −26% early to 4% lately, median −3% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Owner earnings growth −9%/yr
    What this means

    Owner earnings shrank about 9% a year over the record.

  • Worst year 2017 · −80.0% op. margin
    What this means

    Operations went underwater in 2017, understand why before trusting the good years.

  • Share count +2.1%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

  • Dividend record paid
    What this means

    Paid a dividend in 3 of the years on record.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$13.8B
  • Cash & short-term investments$3.7B
  • Receivables$3.5B
  • Inventory$3.2B
  • Other current assets$3.4B
Current liabilities$15.6B
  • Debt due within a year$4.5B
  • Accounts payable$2.7B
  • Other current liabilities$8.4B
Current ratio0.88×all current assets ÷ what's due · Graham looked for 2×
Quick ratio0.67×stricter: inventory excluded
Cash ratio0.23×strictest: cash alone against what's due
Working capital($1.9B)the cushion left after near-term bills
Debt due this year vs. cash$4.5B due · $3.7B cash cash alone won't cover the maturities; it leans on refinancing or operating cash · both figures from the Jun 30, 2026 balance sheet
Revenue, latest quarter vs. a year ago−0.8%the freshest read on whether the business is still growing
Current ratio, recent quarters0.9× → 0.9×
Deeper floors
Tangible book value($11.5B)equity stripped of goodwill & intangibles
Net current asset value($18.3B)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$5.1B$570M of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $17.2B of operating cash; how management split it reads as a deleverager, a meaningful share of cash went to paying down debt.

  • Reinvested$6.2B · 36%
  • Dividends$2.2B · 13%
  • Retained (debt / cash)$8.8B · 51%
  • Returned to owners$2.2B

    20% of the owner earnings the business produced over the span, $2.2B as dividends and $0 as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span debt fell $16.7B and cash and short-term investments rose $2.7B.

  • Net change in share count20.7%

    The diluted count rose from 961M to 1160M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record$0.01/sh

    Paid in 3 of the years on record, the per-share dividend shrinking about 91% a year. It was cut at least once along the way.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Acquisitions & goodwill

from the balance sheet & the 10-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$19.8B49% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equityexceeds itgoodwill alone is larger than the company’s entire book equity; stripped of the acquisition premium, there is no net book worth
Cash spent acquiring$39.4Bover 9 years since fiscal 2015 buying other businesses, against $6.2B of capital spent building over the 10-year record

$29.7B written down across 7 years (2016, 2017, 2018, 2020, 2022, 2023, 2024): goodwill the company has already conceded it overpaid for, charged against earnings. That is roughly 82% of the cash it put into acquisitions over the span. A write-down costs no cash (the cash went out when the deal was signed), but it is management marking its own past judgment to market.

Beside that spending sits $9.9B of cumulative amortization of acquired intangibles charged against earnings since fiscal 2015 — the purchase price of past deals, expensed over time.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and amortization summed across the company's full tagged history, write-downs across the 10-year record, from the company's own filings.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Kåre Schultz$14.7M$7.6M$236M
2022Kåre Schultz$15.5M$17.2M$1.0B
2023Richard Francis$25.7M$26.2M$842M
2024Richard Francis$15.5M$40.9M$749M
2025Richard Francis$19.2M$55.0M$1.1B

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership<1%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio257:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$157M

    The slice of the business handed to employees in shares in fiscal 2025, 0.9% of revenue, equal to 7.3% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Income taxes, Acquisitions, Contingencies as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
TAKTakeda Pharmaceutical Company Limited$28.9B69%11.3%4%18%
TEVATeva Pharmaceutical Industries Limited$17.3B48%-2.2%-2%6%
REGNRegeneron Pharmaceuticals Inc.$14.3B96%2y34.6%21%31%
VTRSViatris$14.3B35%2.5%0%14%
NVSNovartis AG$14.0B126.2%1y126%1y
VRTXVertex Pharmaceuticals Incorporated$12.0B87%31.8%36%34%
BHCBausch Health Companies Inc.$10.3B72%2y5.5%2%13%
ZTSZoetis Inc.$9.5B69%34.2%26%22%
Group median69%21.6%4%20%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Teva Pharmaceutical Industries Limited has delivered.

Teva Pharmaceutical Industries Limited’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.

$

Through the cycle, Teva Pharmaceutical Industries Limited earns about $992M on its 5.7% median owner-earnings margin. This year’s 6.7% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.

Base

The assumptions

9.0% = the 4.65% 10-year Treasury (Aug 19, 2026) + 4.35 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+10%/yr
Owner-earnings growth · ’16→’25−9%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.65%, as of Aug 19, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings $1.3B on 1165M shares outstanding, per the 10-Q cover, as of 2026-06-30; net debt $13.0B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Teva Pharmaceutical Industries Limited (TEVA), the owner's record," https://ownerscorecard.com/c/TEVA, data as of 2026-08-17.

Manual order: ← TER its page in the Manual TEX →

Industry order: ← TBPH the Pharmaceuticals chapter TGTX →